Home

NHS could recoup cost of ineffective drugs

2007-06-04T00:00:00

The National Institute for Health and Clinical Excellence is recommending an innovative deal for an anti-cancer drug. It says patients with multiple myeloma who show a full or partial response to the drug Velcade should be kept on it and be funded by the NHS.

You need to be signed in to read more

HSJ

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

  • All of HSJ.co.uk and our HSJ mobile app
  • News and insight on all areas of public funded healthcare
  • Expert commentary, insight and analysis from industry leaders
  • 9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Subscribe

to HSJ

Sign into your account here